Redcutil (sibutramine hydrochloride monohydrate) is an orally administered treatment for obesity. It is used widely throughout the world by over 8 million people in approximately 70 countries. Outside of the UK it is known as Meridia, Reduxade and Ectiva. It has been licensed for use in the UK since July 2001.
According to British Department of Health, over 200 patients taking Reductil reported adverse reactions, including 2 deaths. In December, 2001, Britain's Drug and Therapeutics Bulletin warned that Reductil had limited benefits and unwanted side effects.
In March, 2002, a petition claimed that in the United States there had been almost 400 serious adverse reactions reported to the Food and Drug Administration since Meridia was first marketed there in February, 1998. Of the adverse reactions reported, these included arrhythmia, cardiovascular problems and in 30 cases, death.
On March 8, 2002, the Italian Health Ministry suspended the sale of Reductil following 50 reports of adverse events and French drug regulators have also reported receiving almost 100 cases of side effects.
We are interested in knowing if you have suffered any adverse reaction which you believe to be associated with the use of Reductil. If you do believe that Reductil has caused you a problem please could you complete the brief online form. We will then be in a position to consider your enquiry in more detail.
If you believe that you might have a legal claim relating to Meridia/Reductil, please complete the online enquiry form or call 0870 024 0558. Your enquiry will be forwarded to a solicitor who specialises in Meridia/Reductil.
If you have any comments in relation to Meridia/Reductil, please use the online discussion forum.
Alexander Harris are proactive and keen and they provided me with an immediate response: Paul, London
